About BPI fold-containing family B member 2
BPI fold-containing family B member 2 (BPIFB2) is a protein
from Homo sapiens identified by UniProt accession
Q8N4F0, 458 residues long.
MolForge cross-references it against 0 known binders and
36 disease associations.
Target properties
| Protein name | BPI fold-containing family B member 2 |
| UniProt accession | Q8N4F0 |
| Gene | BPIFB2 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (36)
Diseases linked to this target (Open Targets).
- lung adenocarcinoma · score 0.19
- ovarian cancer · score 0.18
- glioblastoma multiforme · score 0.17
- endometrial cancer · score 0.15
- squamous cell lung carcinoma · score 0.14
- head and neck squamous cell carcinoma · score 0.12
- hair colour measurement · score 0.04
- non-small cell lung carcinoma · score 0.04
- neoplasm · score 0.02
- blood protein measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N4F0-F1 | alphafold | PREDICTED | 88.84 | — |
Amino-acid sequence (458 residues)
MAWASRLGLL LALLLPVVGA STPGTVVRLN KAALSYVSEI GKAPLQRALQ VTVPHFLDWS GEALQPTRIR ILNVHVPRLH LKFIAGFGVR LLAAANFTFK VFRAPEPLEL TLPVELLADT RVTQSSIRTP VVSISACSLF SGHANEFDGS NSTSHALLVL VQKHIKAVLS NKLCLSISNL VQGVNVHLGT LIGLNPVGPE SQIRYSMVSV PTVTSDYISL EVNAVLFLLG KPIILPTDAT PFVLPRHVGT EGSMATVGLS QQLFDSALLL LQKAGALNLD ITGQLRSDDN LLNTSALGRL IPEVARQFPE PMPVVLKVRL GATPVAMLHT NNATLRLQPF VEVLATASNS AFQSLFSLDV VVNLRLQLSV SKVKLQGTTS VLGDVQLTVA SSNVGFIDTD QVRTLMGTVF EKPLLDHLNA LLAMGIALPG VVNLHYVAPE IFVYEGYVVI SSGLFYQS
Explore BPI fold-containing family B member 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets